New drug cocktail aims to spare bladders in tough cancer

NCT ID NCT07279597

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation in 45 people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can eliminate the cancer and allow patients to keep their bladder after initial chemotherapy. Participants will receive the drugs before, during, and after radiation, with a year of maintenance therapy if they achieve a complete response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab and RC48-ADC (a targeted drug) combined with radiotherapy
What this could lead to: If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, potentially preserving quality of life.
What could go wrong: This is an early phase 2 trial with only 45 participants, so results may not apply to everyone. The combination therapy may cause side effects, and it's not yet proven to be better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.